Stay updated with breaking news from 37555810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price reduced by Barclays from $80.00 to $76.00 in a report issued on Monday, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently weighed in on the stock. Truist Financial cut shares of Gilead […]
Concord Wealth Partners boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 34.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 18,355 shares of the biopharmaceutical company’s stock after purchasing an additional 4,684 shares during the period. Concord Wealth Partners’ holdings in Gilead […]
Kestra Private Wealth Services LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 18.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,645 shares of the biopharmaceutical company’s stock after buying an additional 7,257 shares during the […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lowered by Barclays from $80.00 to $76.00 in a report released on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on GILD. HSBC raised shares of Gilead Sciences […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lowered by Barclays from $80.00 to $76.00 in a research report released on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on GILD. Truist Financial cut […]